Decision for potential approval expected from European Commission in early 2024Submission follows the U.S. FDA...
ISELIN, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
ISELIN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 ISELIN, N.J., Oct. 28, 2022 (GLOBE...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq:...
ISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial...
ISELIN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial...
ISELIN, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
0001649989 false 0001649989 2022-08-11 2022-08-11 iso4217:USD xbrli:shares...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.